Related Experiment Video
Updated: Jul 17, 2025
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Do Heart Failure Biomarkers Influence Heart Failure Treatment Response?
Tiffany Yuen1, Pishoy Gouda1, Robert Margaryan2
1Division of Cardiology, University of Alberta, Edmonton, Canada.
Insights
Heart failure (HF) biomarkers are crucial for diagnosis and prognosis. Future research aims to use these biomarkers to personalize HF treatment and monitor patient response to therapy.
Area of Science:
- Cardiology
- Biomarker Discovery
- Translational Medicine
Background:
- Heart failure (HF) significantly contributes to global cardiac morbidity and mortality.
- Advancements in understanding HF cellular and molecular pathways have identified numerous biomarkers.
- Natriuretic peptides are well-established HF biomarkers for diagnosis and prognosis.
Purpose of the Study:
- To review the current landscape of HF biomarkers.
- To identify novel biomarkers with potential to guide and monitor HF treatment response.
- To explore the evolving role of biomarkers beyond diagnosis and prognostication.
Main Methods:
- Literature review of current HF biomarker research.
- Analysis of established and emerging HF biomarkers.
- Evaluation of biomarker utility in guiding and monitoring HF therapy.
Main Results:
- Numerous HF biomarkers have been identified, but their efficacy in guiding therapy is still under investigation.
- Established biomarkers like natriuretic peptides are vital for HF diagnosis and prognosis.
- Emerging biomarkers show promise for personalizing HF treatment and monitoring therapeutic response.
Conclusions:
- Biomarkers are essential tools in managing heart failure.
- Further research is needed to validate novel biomarkers for guiding pharmacologic therapy.
- Biomarker-guided therapy holds potential for personalized treatment strategies in HF patients.
Purpose Of Review:
Heart failure (HF) is one of the leading causes of cardiac morbidity and mortality around the world. Our evolving understanding of the cellular and molecular pathways of HF has led to the identification and evaluation of a growing number of HF biomarkers. Natriuretic peptides remain the best studied and understood HF biomarkers, with demonstrated clinical utility in the diagnosis and prognostication of HF. Less commonly understood is the utility of HF biomarkers for guiding and monitoring treatment response. In this review, we outline the current HF biomarker landscape and identify novel biomarkers that have potential to influence HF treatment response.
Recent Findings:
An increasing number of biomarkers have been identified through the study of HF mechanisms. While these biomarkers hold promise, they have not yet been proven to be effective in guiding HF therapy. A more developed understanding of HF mechanisms has resulted in an increased number of available pharmacologic HF therapies. In the past, biomarkers have been useful for the diagnosis and prognostication of HF. Future evaluation on their use to guide pharmacologic therapy is ongoing, and there is promise that biomarker-guided therapy will allow clinicians to begin personalizing treatment for their HF patients.
Related Concept Videos
01:30Heart Failure V: Medical Management
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:29Heart Failure II: Pathophysiology
01:22Heart Failure Drugs: β-Blockers
01:30Heart Failure VII: Nursing Interventions
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System